CA2214029A1 - Formulations en ampoule unidose de complexes adn/lipides - Google Patents

Formulations en ampoule unidose de complexes adn/lipides Download PDF

Info

Publication number
CA2214029A1
CA2214029A1 CA002214029A CA2214029A CA2214029A1 CA 2214029 A1 CA2214029 A1 CA 2214029A1 CA 002214029 A CA002214029 A CA 002214029A CA 2214029 A CA2214029 A CA 2214029A CA 2214029 A1 CA2214029 A1 CA 2214029A1
Authority
CA
Canada
Prior art keywords
solution
cationic lipid
plasmid dna
lipid
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002214029A
Other languages
English (en)
Inventor
Magda Marquet
Diana L. Burman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fresh Tracks Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2214029A1 publication Critical patent/CA2214029A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des formulations en ampoule unidose de complexes ADN plasmidique/lipides cationiques, lesquelles sont destinées à une utilisation clinique chez l'homme, et préparées selon plusieurs procédés différents, par exemple, selon un procédé comprenant les étapes consistant: (a) à stériliser en autoclave une solution de lipides cationiques, à un niveau de concentration suffisamment élevé pour empêcher principalement la dégradation des lipides au cours de cette stérilisation; (b) à diluer la solution de lipides cationiques stérilisée de l'étape (a), à un degré suffisant pour empêcher notamment l'agrégation des lipides lors de l'étape (d) ci-après; (c) à stériliser par filtrage une solution d'ADN plasmidique; (d) à ajouter la solution d'ADN plasmidique stérilisée de l'étape (c) à la solution stérilisée et diluée de lipides cationiques de l'étape (b), à un niveau de force ionique inférieur à celui de l'isotonicité, afin de former des complexes ADN/lipides; et (e) à ajuster les complexes ADN/lipides de l'étape (d) afin qu'ils soient proches de l'isotonicité.
CA002214029A 1995-04-25 1996-04-11 Formulations en ampoule unidose de complexes adn/lipides Abandoned CA2214029A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42846395A 1995-04-25 1995-04-25
US08/428,463 1995-04-25

Publications (1)

Publication Number Publication Date
CA2214029A1 true CA2214029A1 (fr) 1996-10-31

Family

ID=23699001

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002214029A Abandoned CA2214029A1 (fr) 1995-04-25 1996-04-11 Formulations en ampoule unidose de complexes adn/lipides

Country Status (4)

Country Link
EP (1) EP0826063A1 (fr)
JP (1) JPH11504631A (fr)
CA (1) CA2214029A1 (fr)
WO (1) WO1996034109A1 (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770715A (en) * 1995-03-22 1998-06-23 Toagosei Co., Ltd. Hammerhead-like nucleic acid analogues and their synthesis
CA2264140A1 (fr) 1996-08-26 1998-03-05 Transgene S.A. Complexes acides nucleiques/lipides cationiques
CA2270396C (fr) * 1996-11-04 2008-03-11 Qiagen Gmbh Reactifs cationiques pour transfection
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
EP1104309B8 (fr) * 1998-08-14 2006-07-05 Valentis Inc. Complexe co-lyophilise comprenant un vecteur d'acide nucleique et un agent de formulation
JP2003502345A (ja) * 1999-06-10 2003-01-21 メリアル ペットまたはスポ−ツ用動物のためのｄｎａワクチン
FR2794648B1 (fr) * 1999-06-10 2003-03-07 Merial Sas Vaccins adn pour animaux de compagnie et de sport
US6943152B1 (en) 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
DE19944262A1 (de) * 1999-09-15 2001-03-29 Cardiogene Gentherapeutische S Pharmazeutische Zusammensetzung in Form eines Nukleinsäure-Lipid-Komplexes, ihre Herstellung und Verwendung in der Gentherapie
US7078388B2 (en) 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
FR2804028B1 (fr) * 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
FR2810888B1 (fr) 2000-06-29 2004-07-30 Merial Sas Vaccin contre la fievre aphteuse
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
EP1545575A4 (fr) 2002-09-19 2006-04-05 Us Gov Health & Human Serv Polypeptides p. ariasi polypeptides p. perniciosus et methodes d'utilisation
MXPA05004714A (es) 2002-10-29 2006-03-17 Us Gov Health & Human Serv Polipeptidos de lutzomyia longipalpis y metodos de uso.
US7354593B2 (en) 2002-12-09 2008-04-08 Merial Limited Coccidial vaccine and methods of making and using same
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
DK1881845T3 (da) 2005-04-25 2010-06-07 Merial Ltd Nipah-virusvacciner
CN101365484A (zh) 2005-08-15 2009-02-11 瓦克辛公司 通过给药非复制型载体化疫苗而进行的对禽类的免疫
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
CA2629522A1 (fr) 2005-11-14 2007-05-18 Merial Limited Therapie genique pour insuffisance renale
JP2009531464A (ja) 2006-03-29 2009-09-03 メリアル リミテッド 連鎖球菌に対するワクチン
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
WO2008062911A1 (fr) 2006-11-24 2008-05-29 Waseda University Réactif pour l'introduction d'une protéine ou d'un gène
UA100692C2 (ru) 2007-05-02 2013-01-25 Мериал Лимитед Днк-плазмиды, имеющие повышенную экспрессию и стабильность
US20090111099A1 (en) * 2007-10-27 2009-04-30 Yongsheng Ma Promoter Detection and Analysis
EP2899203B1 (fr) 2008-05-08 2019-07-10 Boehringer Ingelheim Animal Health USA Inc. Vaccin contre la leishmaniose utilisant un immunogène salivaire de phlébotome
EP3542815A1 (fr) 2008-11-28 2019-09-25 Boehringer Ingelheim Animal Health USA Inc. Vaccin contre la grippe aviaire recombiné et ses utilisations
CN102428099B (zh) 2009-04-03 2016-03-16 梅里亚有限公司 运载新城疫病毒的禽疫苗
MX2011012234A (es) 2009-05-22 2012-03-07 Merial Ltd Plasmido libre de antibiotico.
AR079767A1 (es) 2009-12-28 2012-02-15 Merial Ltd Antigeno ndv (virus de la enfermedad de newcastle) recombinante y usos del mismo
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
AU2011224188B2 (en) 2010-03-12 2015-01-22 Boehringer Ingelheim Animal Health USA Inc. Bluetongue virus recombinant vaccines and uses thereof
WO2012030720A1 (fr) 2010-08-31 2012-03-08 Merial Limited Vaccins contre le virus herpétique à base de vecteurs du virus de la maladie de newcastle
WO2012145577A1 (fr) 2011-04-20 2012-10-26 Merial Limited Vaccin antirabique avec adjuvant à profil de viscosité amélioré
MX361804B (es) 2011-05-27 2018-12-17 Boehringer Ingelheim Animal Health Usa Inc Vacunas genéticas contra el virus hendra y el virus nipah.
WO2012166493A1 (fr) 2011-06-01 2012-12-06 Merial Limited Administration sans aiguille de vaccins contre le vsrrp
IN2014CN00547A (fr) 2011-07-20 2015-04-03 Merial Ltd
HUE035774T2 (en) 2011-08-12 2018-05-28 Merial Inc Biological substances, in particular vaccines, preserved by vacuum
CN104203274B (zh) 2012-02-14 2017-09-08 梅里亚股份有限公司 轮状病毒亚单位疫苗及其制备和使用的方法
CA2864119C (fr) 2012-02-14 2022-05-24 Merial Limited Vecteurs poxviraux recombinants exprimant a la fois les proteines de la rage et ox40, et vaccins fabriques a partir de ceux-ci
ES2711878T3 (es) 2012-03-20 2019-05-08 Merial Inc Vacuna contra el virus del herpes equino 1 recombinante que contiene glicoproteína C mutada y usos de la misma
WO2013143555A1 (fr) 2012-03-26 2013-10-03 Biontech Ag Formulation d'arn pour immunothérapie
ES2664069T3 (es) 2012-06-13 2018-04-18 Merial, Inc. Vacunas contra BTV y AHSV de genoma reordenado
WO2015048115A1 (fr) 2013-09-25 2015-04-02 Zoetis Llc Composition vaccinale divergente anti-pcv2b et ses procédés d'utilisation
CA2948845C (fr) 2014-05-14 2022-05-31 Merial, Inc. Procedes de lyophilisation et de rehydratation de produits biologiques
CA2990643C (fr) 2015-06-23 2023-10-17 Merial, Inc. Vecteurs viraux recombines contenant une proteine mineure de prrsv et procedes de preparation et d'utilisation de ceux-ci
EP3313440A2 (fr) 2015-06-26 2018-05-02 Merial, Inc. Vaccins inactivés de la grippe canine, et leurs méthodes de production et d'utilisation
PL3355915T3 (pl) 2015-09-29 2024-03-25 Boehringer Ingelheim Animal Health USA Inc. Szczepionki zawierające cząstki wirusopodobne (VLP) parwowirusa psów (CPV) i ich zastosowania
RU2714428C2 (ru) 2015-11-23 2020-02-14 Мериал, Инк. Слитые белки fmdv-e2 и их применение
TWI760322B (zh) 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途
ES2960939T3 (es) * 2018-04-25 2024-03-07 Ethris Gmbh Agentes crioprotectores para formulaciones particuladas
JP7271026B1 (ja) * 2021-12-28 2023-05-11 株式会社Hyperion Drug Discovery 遺伝子導入細胞の免疫応答を回避させるための剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990003808A1 (fr) * 1988-10-07 1990-04-19 The Liposome Company, Inc. Traitement thermique de liposomes
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
DE4131562A1 (de) * 1991-09-18 1993-03-25 Medac Klinische Spezialpraep Arzneistofftraeger aus festen lipidteilchen-feste lipidnanosphaeren (sln)

Also Published As

Publication number Publication date
WO1996034109A1 (fr) 1996-10-31
EP0826063A1 (fr) 1998-03-04
JPH11504631A (ja) 1999-04-27

Similar Documents

Publication Publication Date Title
CA2214029A1 (fr) Formulations en ampoule unidose de complexes adn/lipides
DE69725878T2 (de) Zusammensetzungen zur polynukleotidabgabe
US8771728B2 (en) Stable lipid-comprising drug delivery complexes and methods for their production
US6008202A (en) Stable lipid-comprising drug delivery complexes and methods for their production
US7070807B2 (en) Branched histidine copolymers and methods for using same
EP0795015B1 (fr) Plasmides appropries a l'expression de l'il-2
US7163695B2 (en) Histidine copolymer and methods for using same
DE69434447T2 (de) Für die gentherapie verwendbare plasmide
US20050025821A1 (en) Lipid-comprising drug delivery complexes and methods for their production
JP2001508815A (ja) カチオン性ポリマー／脂質核酸送達ビヒクル
CA2340416C (fr) Formulation protegee, dans un seul flacon, pour molecules d'acide nucleique, ses procedes de fabrication par melangeage en ligne, produits et procedes associes
JP2001526181A (ja) 遺伝子輸送体であるグラフト共重合体
EP0931156A2 (fr) Expression de genes, systemes d'apport et utilisations
EP4424701A1 (fr) Vecteur de polypeptide cyclique pour une administration efficace d'un acide nucléique, et ses variants
JPWO2005054486A1 (ja) 遺伝子導入試薬調製法
EP4311559A1 (fr) Nanoparticules et peptides pour l'administration de cargos aux chondrocytes
JP2001502736A (ja) キトサン含有組成物
JP2003531181A (ja) 核酸を細胞に投与するための粒状複合体
AU2003238331B2 (en) Delivery system for pharmaceutical agents
AU8724001A (en) Gene expression and delivery systems and uses

Legal Events

Date Code Title Description
FZDE Dead